Absolute quantitation of radioactivity using the buildup factor

The effect of volume-of-interest misregistration on quantitative planar activity and dose estimation

In targeted radionuclide therapy (TRT), dose estimation is essential for treatment planning and tumor dose response studies. Dose estimates are typically based on a time series of whole-body conjugate view planar or SPECT scans of the patient acquired after administration of a planning dose. Quantifying the activity in the organs from these studies is an essential part of dose estimation. The quantitative planar (QPlanar) processing method involves accurate compensation for image degrading factors and correction for organ and background overlap via the combination of computational models of the image formation process and 3D volumes of interest defining the organs to be quantified. When the organ VOIs are accurately defined, the method intrinsically compensates for attenuation, scatter and partial volume effects, as well as overlap with other organs and the background. However, alignment between the 3D organ volume of interest (VOIs) used in QPlanar processing and the true organ projections in the planar images is required. The aim of this research was to study the effects of VOI misregistration on the accuracy and precision of organ activity estimates obtained using the QPlanar method. In this work, we modeled the degree of residual misregistration that would be expected after an automated registration procedure by randomly misaligning 3D SPECT/CT images, from which the VOI information was derived, and planar images. Mutual information-based image registration was used to align the realistic simulated 3D SPECT images with the 2D planar images. The residual image misregistration was used to simulate realistic levels of misregistration and allow investigation of the effects of misregistration on the accuracy and precision of the QPlanar method. We observed that accurate registration is especially important for small organs or ones with low activity concentrations compared to neighboring organs. In addition, residual misregistration gave rise to a loss of precision in the activity estimates that was on the order of the loss of precision due to Poisson noise in the projection data. These results serve as a lower bound on the effects of misregistration on the accuracy and precision of QPlanar activity estimate and demonstrate that misregistration errors must be taken into account when assessing the overall precision of organ dose estimates.

Effects of shortened acquisition time on accuracy and precision of quantitative estimates of organ activity

PURPOSE

Quantitative estimation of in vivo organ uptake is an essential part of treatment planning for targeted radionuclide therapy. This usually involves the use of planar or SPECT scans with acquisition times chosen based more on image quality considerations rather than the minimum needed for precise quantification. In previous simulation studies at clinical count levels (185 MBq 111In), the authors observed larger variations in accuracy of organ activity estimates resulting from anatomical and uptake differences than statistical noise. This suggests that it is possible to reduce the acquisition time without substantially increasing the variation in accuracy.

METHODS

To test this hypothesis, the authors compared the accuracy and variation in accuracy of organ activity estimates obtained from planar and SPECT scans at various count levels. A simulated phantom population with realistic variations in anatomy and biodistribution was used to model variability in a patient population. Planar and SPECT projections were simulated using previously validated Monte Carlo simulation tools. The authors simulated the projections at count levels approximately corresponding to 1.5-30 min of total acquisition time. The projections were processed using previously described quantitative SPECT (QSPECT) and planar (QPlanar) methods. The QSPECT method was based on the OS-EM algorithm with compensations for attenuation, scatter, and collimator-detector response. The QPlanar method is based on the ML-EM algorithm using the same model-based compensation for all the image degrading effects as the QSPECT method. The volumes of interests (VOIs) were defined based on the true organ configuration in the phantoms. The errors in organ activity estimates from different count levels and processing methods were compared in terms of mean and standard deviation over the simulated phantom population.

RESULTS

There was little degradation in quantitative reliability when the acquisition time was reduced by half for the QSPECT method (the mean error changed by < 1%, e.g., 0.9%-0.3% = 0.6% for the spleen). The magnitude of the errors and variations in errors for large organ with high uptake were still acceptable for 1.5 min scans, even though the errors were slightly larger than those for the 30 min scans (i.e., < 2% for liver, < 3% for heart). The errors over the ranges of scan times studied for the QPlanar method were all within 0.3% for all organs.

CONCLUSIONS

These data indicate that, for the purposes of organ activity estimation, acquisition times could be reduced at least by a factor of 2 for the QSPECT and QPlanar methods with little effect on the errors in organ activity estimates. The acquisition time can be further reduced for the QPlanar method, assuming well-registered VOIs are available and the activity distribution in organs can be treated as uniform. Although the differences in accuracy and precision were statistically significant for all the acquisition times shorter than 30 min, the magnitude of the changes in accuracy and precision were small and likely not clinically important. The reduction in SPECT acquisition time justified by this study makes the use of SPECT a more clinically practical alternative to conventional planar scanning for targeted radiotherapy treatment planning.

Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies

The estimation of organ residence time is essential for high-dose myeloablative regimens in radioimmunotherapy (RIT). Frequently, this estimation is based on a series of simple planar scans and planar processing. The authors previously performed a simulation study which demonstrated that the accuracy of this methodology is limited compared to a hybrid planar/SPECT residence time estimation method. In this work the authors applied this hybrid method to data from a clinical trial of high-dose myeloablative yttrium-90 ibritumomab tiuxetan therapy. Image data acquired from 18 patients were comprised of planar scans at five time points ranging from 1 to 144 h postinjection and abdominal and thoracic SPECT/CT scans obtained at 24 h postinjection. The simple planar processing method used in this work was based on the geometric mean method with energy window based scatter compensation. No explicit background subtraction nor object or source thickness corrections were performed. The SPECT projections were reconstructed using iterative reconstruction with compensations for attenuation, scatter, and full collimator-detector response. Large differences were observed when residence times were estimated using the simple planar method compared to the hybrid method. The differences were not constant but varied in magnitude and sign. For the dose-limiting organ (liver), the average difference was -18% and variation in the difference was 19%, similar to the differences observed in a previously reported simulation study. The authors also looked at the relationship between the weight of the patient and the liver residence time and found that there was no meaningful correlation for either method. This indicates that weight would not be an adequate proxy for an experimental estimate of residence time when choosing the activity to administer for therapy. The authors conclude that methods such as the simple planar method used here are inadequate for RIT treatment planning. More sophisticated methods, such as the hybrid SPECT/planar method investigated here, are likely to be better predictors of organ dose and, as a result, organ toxicities.

Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--Monte Carlo simulation studies

Estimating the residence times in tumor and normal organs is an essential part of treatment planning for radioimmunotherapy (RIT). This estimation is usually done using a conjugate view whole body scan time series and planar processing. This method has logistical and cost advantages compared to 3-D imaging methods such as Single photon emission computed tomography (SPECT), but, because it does not provide information about the 3-D distribution of activity, it is difficult to fully compensate for effects such as attenuation and background and overlapping activity. Incomplete compensation for these effects reduces the accuracy of the residence time estimates. In this work we compare residence times estimates obtained using planar methods to those from methods based on quantitative SPECT (QSPECT) reconstructions. We have previously developed QSPECT methods that provide compensation for attenuation, scatter, collimator-detector response, and partial volume effects. In this study we compared the use of residence time estimation methods using QSPECT to planar methods. The evaluation was done using the realistic NCAT phantom with organ time activities that model (111)In ibritumomab tiuxetan. Projection data were obtained using Monte Carlo simulations (MCS) that realistically model the image formation process including penetration and scatter in the collimator-detector system. These projection data were used to evaluate the accuracy of residence time estimation using a time series of QSPECT studies, a single QSPECT study combined with planar scans and the planar scans alone. The errors in the residence time estimates were 3.8%, 15%, and 2%-107% for the QSPECT, hybrid planar/QSPECT, and planar methods, respectively. The quantitative accuracy was worst for pure planar processing and best for pure QSPECT processing. Hybrid planar/QSPECT methods, where a single QSPECT study was combined with a series of planar scans, provided a large and statistically significant improvement in quantitative accuracy for most organs compared to the planar scans alone, even without sophisticated attention to background subtraction or thickness corrections in planar processing. These results indicate that hybrid planar/QSPECT methods are generally superior to pure planar methods and may be an acceptable alternative to performing a time series of QSPECT studies.

Comparison of conventional, model-based quantitative planar, and quantitative SPECT image processing methods for organ activity estimation using In-111 agents

Accurate quantification of organ radionuclide uptake is important for patient-specific dosimetry. The quantitative accuracy from conventional conjugate view methods is limited by overlap of projections from different organs and background activity, and attenuation and scatter. In this work, we propose and validate a quantitative planar (QPlanar) processing method based on maximum likelihood (ML) estimation of organ activities using 3D organ VOIs and a projector that models the image degrading effects. Both a physical phantom experiment and Monte Carlo simulation (MCS) studies were used to evaluate the new method. In these studies, the accuracies and precisions of organ activity estimates for the QPlanar method were compared with those from conventional planar (CPlanar) processing methods with various corrections for scatter, attenuation and organ overlap, and a quantitative SPECT (QSPECT) processing method. Experimental planar and SPECT projections and registered CT data from an RSD Torso phantom were obtained using a GE Millenium VH/Hawkeye system. The MCS data were obtained from the 3D NCAT phantom with organ activity distributions that modelled the uptake of (111)In ibritumomab tiuxetan. The simulations were performed using parameters appropriate for the same system used in the RSD torso phantom experiment. The organ activity estimates obtained from the CPlanar, QPlanar and QSPECT methods from both experiments were compared. From the results of the MCS experiment, even with ideal organ overlap correction and background subtraction, CPlanar methods provided limited quantitative accuracy. The QPlanar method with accurate modelling of the physical factors increased the quantitative accuracy at the cost of requiring estimates of the organ VOIs in 3D. The accuracy of QPlanar approached that of QSPECT, but required much less acquisition and computation time. Similar results were obtained from the physical phantom experiment. We conclude that the QPlanar method, based on 3D organ VOIs and accurate models of the projection process, provided a substantial increase in accuracy of organ activity estimates from planar images compared to CPlanar processing and had accuracy approaching that of QSPECT.

An overview of attenuation and scatter correction of planar and SPECT data for dosimetry studies

A number of factors impact the accuracy of activity quantitation in planar and single photon emission computed tomographic (SPECT) imaging. Two important such factors are attenuation and scattering in the medium containing the activity. The first removes photons which otherwise would have been included in the images, and the second adds events to the images from photons which would not have otherwise been imaged. A number of methods have been developed to compensate for these biases to activity quantitation. This review will briefly introduce planar quantitation which is commonly used for dosimetric purposes, and then present a slightly more detailed overview of SPECT quantitation which is arguably more accurate. It will conclude by cautioning users of commercial reconstruction software to validate it for quantitation before using it for dosimetric purposes.

RMDP: a dedicated package for 131I SPECT quantification, registration and patient-specific dosimetry

The limitations of traditional targeted radionuclide therapy (TRT) dosimetry can be overcome by using voxel-based techniques. All dosimetry techniques are reliant on a sequence of quantitative emission and transmission data. The use of (131)I, for example, with NaI or mIBG, presents additional quantification challenges beyond those encountered in low-energy NM diagnostic imaging, including dead-time correction and additional photon scatter and penetration in the camera head. The Royal Marsden Dosimetry Package (RMDP) offers a complete package for the accurate processing and analysis of raw emission and transmission patient data. Quantitative SPECT reconstruction is possible using either FBP or OS-EM algorithms. Manual, marker- or voxel-based registration can be used to register images from different modalities and the sequence of SPECT studies required for 3-D dosimetry calculations. The 3-D patient-specific dosimetry routines, using either a beta-kernel or voxel S-factor, are included. Phase-fitting each voxel's activity series enables more robust maps to be generated in the presence of imaging noise, such as is encountered during late, low-count scans or when there is significant redistribution within the VOI between scans. Error analysis can be applied to each generated dose-map. Patients receiving (131)I-mIBG, (131)I-NaI, and (186)Re-HEDP therapies have been analyzed using RMDP. A Monte-Carlo package, developed specifically to address the problems of (131)I quantification by including full photon interactions in a hexagonal-hole collimator and the gamma camera crystal, has been included in the dosimetry package. It is hoped that the addition of this code will lead to improved (131)I image quantification and will contribute towards more accurate 3-D dosimetry.

Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components

Hematologic toxicity limits the radioactivity that may be administered for radiolabeled antibody therapy. This work examines approaches for obtaining biodistribution data and performing dosimetry when the administered antibody is known to bind to a cellular component of blood, bone, or marrow. Marrow dosimetry in this case is more difficult because the kinetics of antibody clearance from the blood cannot be related to the marrow. Several approaches for obtaining antibody kinetics in the marrow are examined and evaluated. The absorbed fractions and S factors that should be used in performing marrow dosimetry are also examined and the effect of including greater anatomical detail is considered. The radiobiology of the red marrow is briefly reviewed. Recommendations for performing marrow dosimetry when the antibody binds to the marrow are provided.

A method for calibrating three-dimensional positron emission tomography without scatter correction

Calibration for three-dimensional positron emission tomography (3D PET) using a uniform cylinder and cross-calibration with aliquots requires correction for scatter and attenuation. Thus the accuracy of the calibration is dependent on the scatter correction method, and on the applicability of the scatter correction for different regions of the body. A method has been developed which provides a calibration which does not require correction for scatter or attenuation, making it generally applicable and independent of the scatter correction. The method has been previously described for measurement of the absolute sensitivity of tomographic devices. This approach has been extended to give a calibration of the PET camera "in air" in units of kBq/pixel. The reconstructed images are multiplied by this factor to give accurate activity concentrations, after attenuation and scatter correction. The method has been used with a fully 3D filtered backprojection (reprojection) algorithm and iterative convolution-subtraction scatter correction on data from an ECAT 953B. Using this method 3D PET images have been calibrated to within +/-5% accuracy, but this is highly dependent on the accuracy of the scatter correction. The method described here is practical and provides a means of calibrating a 3D PET system without the need for correction for scatter or attenuation of the calibration data.

Treatment planning for radio-immunotherapy

To foster the success of clinical trials in radio-immunotherapy (RIT), one needs to determine (i) the quantity and spatial distribution of the administered radionuclide carrier in the patient over time, (ii) the absorbed dose in the tumour sites and critical organs based on this distribution and (iii) the volume of tumour mass(es) and normal organs from computerized tomography or magnetic resonance imaging and appropriately correlated with nuclear medicine imaging techniques (such as planar, single-photon emission computerized tomography or positron-emission tomography). Treatment planning for RIT has become an important tool in predicting the relative benefit of therapy based on individualized dosimetry as derived from diagnostic, pre-therapy administration of the radiolabelled antibody. This allows the investigator to pre-select those patients who have 'favorable' dosimetry characteristics (high time-averaged target: non-target ratios) so that the chances for treatment success may be more accurately quantified before placing the patient at risk for treatment-related organ toxicities. The future prospects for RIT treatment planning may yield a more accurate correlation of response and critical organ toxicity with computed absorbed dose, and the compilation of dose-volume histogram information for tumour(s) and normal organ(s) such that computing tumour control probabilities and normal tissue complication probabilities becomes possible for heterogeneous distributions of the radiolabelled antibody. Additionally, radiobiological consequences of depositing absorbed doses from exponentially decaying sources must be factored into the interpretation when trying to compute the effects of standard external beam isodose display patterns combined with those associated with RIT.

Transmission-based scatter correction of 180 degrees myocardial single-photon emission tomographic studies

Meaningful comparison of single-photon emission tomographic (SPET) reconstructions for data acquired over 180 degrees or 360 degrees can only be performed if both attenuation and scatter correction are applied. Convolution subtraction has appeal as a practical method for scatter correction; however, it is limited to data acquired over 360 degrees. A new algorithm is proposed which can be applied equally well to data acquired over 180 degrees or 360 degrees. The method involves estimating scatter based on knowledge of reconstructed transmission data in combination with a reconstructed estimate of the activity distribution, obtained using attenuation correction with broad beam attenuation coefficients. Processing is implemented for planes of activity parallel to the projection images for which a simplified model for the scatter distribution may be applied, based on the measured attenuation. The appropriate broad beam (effective) attenuation coefficients were determined by considering the scatter buildup equation. It was demonstrated that narrow beam attenuation coefficients should be scaled by 0.75 and 0.65 to provide broad beam attenuation coefficients for technetium-99m and thallium-201 respectively. Using a thorax phantom, quantitative accuracy of the new algorithm was compared with conventional transmission-based convolution subtraction (TDCS) for 360 degrees data. Similar heart to lung contrasts were achieved and correction of 180 degrees data yielded a 10.4% error for cardiac activity compared to 5.2% for TDCS. Contrast for myocardium to ventricular cavity was similarly good for scatter-corrected 180 degrees and 360 degrees data, in contrast to attenuation-corrected data, where contrast was significantly reduced. The new algorithm provides a practical method for correction of scatter applicable to 180 degrees myocardial SPET.

Planar imaging quantification using 3D attenuation correction data and Monte Carlo simulated buildup factors

A new method to correct for attenuation and the buildup of scatter in planar imaging quantification is presented. The method is based on the combined use of 3D density information provided by computed tomography to correct for attenuation and the application of Monte Carlo simulated buildup factors to correct for buildup in the projection pixels. CT and nuclear medicine images were obtained for a purpose-built nonhomogeneous phantom that models the human anatomy in the thoracic and abdominal regions. The CT transverse slices of the phantom were converted to a set of consecutive density maps. An algorithm was developed that projects the 3D information contained in the set of density maps to create opposing pairs of accurate 2D correction maps that were subsequently applied to planar images acquired from a dual-head gamma camera. A comparison of results obtained by the new method and the geometric mean approach based on published techniques is presented for some of the source arrangements used. Excellent results were obtained for various source-phantom configurations used to evaluate the method. Activity quantification of a line source at most locations in the nonhomogeneous phantom produced errors of less than 2%. Additionally, knowledge of the actual source depth is not required for accurate activity quantification. Quantification of volume sources placed in foam, Perspex and aluminium produced errors of less than 7% for the abdominal and thoracic configurations of the phantom.

A Monte Carlo evaluation of the channel ratio scatter correction method

Several methods exist to eliminate the contribution of scattered photons during imaging. One of these, the channel ratio (CR) scatter correction technique, uses the change in the ratio of counts from two symmetrical adjacent energy windows straddling the energy photopeak. The accuracy of the results depends upon the assumption that the ratio of the scatter components in the two windows (H value) is constant and is independent of the relative size of the scatter contribution. In this study a Monte Carlo simulation was used to investigate the behaviour of the scatter component for different source sizes at different depths. Four disc sources containing a 99Tcm solution were simulated at different depths as imaged with a scintillation camera. Two 10% energy windows with 5% offsets to either side of the 140 keV photopeak of 99Tcm were used. The ratio of the scattered counts in the lower energy window to the scattered counts in the upper window (true H value) was determined from the simulation for each source at every depth. Since it is impossible to measure the true H value at different organ depths during a clinical study, the use of an average H value was considered. Scatter correction was applied to the images simulated at the various depths in water. The geometric mean was calculated and attenuation correction performed assuming mono-exponential attenuation. For quantitation purposes the corrected counts were expressed in terms of a references source. The choice of the reference source yielding the best quantitative results was also investigated. Results of this Monte Carlo simulation study show that although the true H value depends on both source size and depth of the source in the scattering medium, the CR scatter correction technique can be applied successfully when an average H value is used.

Pharmacokinetics and dosimetry of [111In] F(ab')2 fragments against prostatic acid phosphatase after intraprostatic injection for immunoscintigraphy in prostate cancer

The purpose of this study was to investigate the pharmacokinetics and dosimetry of using [111In]-labelled F(ab')2 fragments against prostate acid phosphatase (FC-3001, Orion Corporation Farmos, Finland) for the detection of metastatic prostate cancer. Five patients in all were subjected to intraprostatic injection of 1 mg FC-3001 labelled with 85-100 MBq [111In]. In four of the patients the biodistribution was studied by sequential whole-body counting, gamma-camera scintigraphy of the abdomen in antero-posterior and postero-anterior projections. Blood and urine samples were collected sequentially up to 72 h after injection. Initially, significant amounts of antibody fragments were released from the site of injection. After the first 4 h, 22.0% of injected antibody (2.2-41.3% ID) remained in the prostate and was slowly released with a final half-life of 80.4 h (49.9-141.8 h). Labelled antibody appeared in the blood shortly after injection and was cleared from the blood with a final half-life of 27.7-300.9 h. The liver, the bone marrow and, in two patients, the kidneys accumulated antibody fragments in significant amounts during the period of investigation. An apparent relationship between the initial whole-body clearance and renal uptake is described. The effective dose averaged 0.37 mSv/MBq (range 0.24-0.52 mSv/MBq). The highest equivalent doses were received by the kidneys (0.46-2.81 mGy/MBq) the liver (0.44-1.59 mGy/MBq) and the bone marrow (0.37-0.57 mGy/MBq). Only in two of the patients with known metastases were pathological foci seen. The disappointing imaging results were probably caused by the biphasic release of antibody from the prostate, and indicates that intraprostatic injection of this antibody has no advantage for imaging, as well as being unpleasant for the patient. The biodistribution of the antibody following release from the prostate is similar to but more variable than the biodistribution seen in patients after intravenous injection of labelled antibodies.

Quantitation of 211At in small volumes for evaluation of targeted radiotherapy in animal models

We have evaluated SPECT and two planar imaging methods, geometric mean (GM) and buildup factor (BF), for their potential to quantitate in vivo 211At distributions in rat spinal subarachnoid spaces using phantom studies. The use of medium-energy collimators and the small diameter (3 mm) of the subarachnoid space complicate quantitation. Net activities from distributions in various backgrounds were obtained using a large region of interest with background subtraction. Results showed quantitation accuracy within 10% for SPECT and BF in low backgrounds increasing to 25% at higher background levels while GM errors ranged from 20 to 45%. We have also obtained images of [211At]astatide distributions, administered intrathecally, in rats.

Scatter correction in scintigraphy: the state of the art

In scintigraphy, the detection of scattered photons degrades both visual image analysis and quantitative accuracy. Many methods have been proposed and are still under investigation to cope with scattered photons. The main features of the problem of scattering in radionuclide imaging are presented first, to provide a sound foundation for a critical review of the existing scatter correction techniques. These are described using a classification relating to their aims and principles. Their theoretical potentials are analysed, as well as the difficulties of their practical implementation. Finally, the problems of their evaluation and comparison are discussed.

Quantification of technetium-99m lung radioactivity from planar images

Six methods of quantifying technetium-99m lung uptake from planar gamma camera images were evaluated. Camera sensitivities, the broad beam attenuation coefficient and build-up factors were derived from suitable phantom measurements. The accuracy of the methods was evaluated by quantifying the lung uptake of 99mTc macroaggregated albumin (MAA) in ten patients and assuming complete trapping by the lung of the known activity of injected MAA particles. Three methods based on published techniques which related the count rate from an image of a lung to that from a lung phantom were the least accurate, producing lung activities which were typically about 70% of the injected activity. Of the other three techniques, the depth-dependent build-up factor method was slightly more accurate than the geometric mean and the depth-independent build-up factor methods, producing average values (+/- SD) of lung activity which were 100% +/- 3%, 106% +/- 3% and 101% +/- 5%, respectively, of the injected activity. To measure lung uptake, all of these latter three methods required an attenuation correction with a flood source transmission scan, and therefore their accuracy was affected by the variation in the activity distribution and attenuation across an image of the thorax.

Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy

Myelosuppression has been identified as the dose-limiting toxicity in radioimmunotherapy studies. Accurate bone marrow dosimetry is, therefore, necessary to evaluate bone marrow toxicity which may result from systemic cancer treatment with radiolabeled monoclonal antibodies. Dose to the red marrow was determined in 20 patient studies with 131I labeled anti-carcinoembryonic antigen, anti-alpha-feto-protein, or anti-human chorionic gonadotropin monoclonal antibody for diagnosis or treatment of diverse metastatic carcinomas, using a new technique involving sacral scintigraphy and a previously reported blood-based methodology. For the sacral technique, anterior and posterior gamma camera images of the pelvis were obtained at multiple times. Regions of interest were drawn around the sacrum in order to quantitate activity uptake as a function of time using the conjugate view counting method. Cumulated activity in red marrow was determined by curve integration and division by 0.099, since it has been estimated that 9.9% of the total red marrow is contained in the sacrum of the adult. Red marrow doses were then obtained by multiplying the cumulated activities by the appropriate S factor. These doses were compared to red marrow doses obtained from serial whole blood samples taken from these patients. Cumulated activity in the red marrow was determined from the blood with the assumption that the activity concentration in the blood and red marrow were equal. The mean red marrow dose per injected activity was 2.0 +/- 0.9 rad/mCi using the sacral data and 2.7 +/- 1.3 rad/mCi using the blood data (P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Quantitative SPECT in radiation dosimetry

Accurate and precise radiation dosimetry is critical for the successful therapeutic application of systemically administered radionuclides, including, of course, radionuclides in the form of radiolabeled antibody. This requires determination, based on discrete serial measurements, of the time-dependent concentrations and/or total amounts of radioactivity in situ in order to calculate source region cumulated activities. Based on extensive studies (with clinically realistic numbers of counts and accuracies of the order of 10%) in simple geometric phantoms, in complex anthropomorphic phantoms, in animal models, and in humans, quantitative rotating scintillation camera-based single-photon emission computed tomography (SPECT) now appears to be a practical approach to such measurements. The basis of the quantitative imaging capability of a three-dimensional imaging modality such as SPECT is the elimination in the reconstructed image of counts emanating from activity surrounding the source region. Subject to considerations such as the reconstruction algorithm, attenuation and scatter corrections, and, most importantly, statistical uncertainty, the counts in a pixel in a reconstructed image are therefore directly proportional to the actual counts emanating from the corresponding voxel in situ. Among intrinsic, pre-processing, and post-processing attenuation corrections, post-processing algorithms, the most widely used approach in current commercial SPECT systems, have proven adequate in uniformly attenuating parts of the body (eg, abdomen, pelvis), subject to accurate delineation of the body contour. Although a number of sophisticated scatter correction methods have been developed, the lack of explicit scatter correction has, in practice, not been a major impediment to reasonably accurate quantitative SPECT imaging, despite scattered radiation representing up to 50% of the counts in a large source region (eg, liver). Because of its mathematical propagation in the image reconstruction process, statistical uncertainty (ie, "noise") in SPECT is far greater than would be expected if it were distributed according to Poisson statistics, as in planar imaging. The low "single slice" sensitivity of rotating scintillation camera-based SPECT is therefore the principal limitation of practical quantitative SPECT. Accordingly, absolute quantitation of count-limited clinical images has been accomplished using a judiciously selected "non-ramp" filter function. In summary, reasonable quantitative SPECT imaging is now feasible clinically, even without sophisticated scatter corrections, at least in uniformly attenuating parts of the body.(ABSTRACT TRUNCATED AT 400 WORDS)

Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma

Radiation absorbed-dose estimates and treatment planning are reported for 11 patients with hepatoma who were administered 90Y-labeled polyclonal antiferritin IgG for therapy in a Phase 1-2 trial. Dosimetric studies included quantitation of the localization and clearance of 111In-labeled antiferritin IgG in tumor and normal tissues and computer-assisted tumor and normal liver volumetrics from X ray CT scans. For the group of patients studied, hepatoma volumes at the time of treatment ranged from 135 to 3442 cm3. Quantitative 111In antiferritin imaging prior to and following 600 or 900 cGy of external-beam irradiation of the primary tumor demonstrated that tumor uptake increased 1.1 to 5.8-fold (mean 2.8) following external beam. In contrast, changes in uptake of radiolabeled antiferritin in normal liver ranged from 0.35 to 2.1-fold (mean 0.93) after external irradiation. Administered activities of 90Y antiferritin ranged from 8 to 37 mCi and were dependent on tumor volume and tumor localization of radiolabeled antiferritin. Following external-beam irradiation, tumor dose rates achieved with 90Y antiferritin ranged from 10 to 20 cGy/hr and normal liver dose rates from 1.1 to 5.7 cGy/h. The corresponding absorbed dose in hepatomas ranged from 900 to 2150 cGy and in normal liver from 80 to 650 cGy. After external-beam irradiation, tumor and normal liver uptake of 90Y antiferritin was consistent with that of 131I antiferritin.

Double peak attenuation method for estimating organ location

Radioactive sources of finite volume containing 133Xe, 67Ga, 99Tcm and 111In were used to measure the attenuation coefficient, mu, in water at six different energies in the range 80-296 keV using an Anger camera. The experimental accuracy was about 7% for the volume range from 40-225 ml when corrections were made for background. The same radioactive sources were used to measure zero attenuation count rates per unit of activity. The theoretical basis was also derived, which confirms our experimental findings, i.e. the measurement of the thickness of the attenuator using a dual energy method. The determination of the linear attenuation coefficient in the broad-beam geometry situation is possible by accounting for cross-talk, scatter and out-of-target activity. By correcting for the broad-beam geometry, agreement with the narrow-beam geometry linear attenuation coefficient was obtained. We also demonstrate the use of the technique to accurately determine the depth of the organ using two separate energies. This methodology is independent of the organ volume for determination of the depth. It is hoped that our findings will provide a better understanding of the photon interactions when extended sources are used. Such a knowledge can also be applied to organ volume measurements.

Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancers

Results of dosimetric studies are reported for 30 patients with hepatoma and 5 patients with primary hepatic cholangiocarcinoma who received treatment with 131I-labeled polyclonal antibodies. Studies included liver and tumor volume computations from X-ray CT scans, in vivo quantitation of the activity of radiolabeled antibodies in hepatic tumors and normal liver tissue, and effective half-life measurements. Twenty-two patients with hepatoma were administered 131I-labeled polyclonal anti-ferritin. Five hepatoma patients, who were AFP-positive, were administered anti-alpha-fetoprotein (AFP). Three patients with AFP-positive hepatomas received both 131I-labeled anti-ferritin and anti-AFP in a bolus. The five cholangiocarcinoma patients were treated with 131I-labeled anti-carcinoembryonic antigen (CEA). For administered activities of 30 mCi on day 0 and 20 mCi on day 5, mean values of the radiation dose to hepatomas were approximately 1100 rads for anti-ferritin, 350 rads for anti-AFP, and 960 rads for the combination of anti-ferritin and anti-AFP. Polyclonal anti-ferritin has, therefore, become the antibody of choice in the treatment of hepatoma. The radiation dose to cholangiocarcinomas from 131I-labeled anti-CEA and administered activities of 20 mCi on day 0 and 10 mCi on day 5 was approximately 620 rads. Total-body irradiation for these injection schedules ranged from 30 to 50 rads.